Moolec Science (MLECW) Share-based Compensation (2022 - 2025)
Moolec Science (MLECW) posted Share-based Compensation of $7.3 million for Q4 2025, little changed sequentially from $7.3 million in Q2 2025, and up 258.21% YoY from $2.0 million in Q4 2024.
Moolec Science (MLECW) Share-based Compensation (2022 - 2025) Analysis & Trends
Moolec Science has reported Share-based Compensation for 4 years, with the latest figure at $7.3 million in Q4 2025.
- Quarterly Share-based Compensation rose 258.21% year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (up 258.21% YoY) and the FY2025 annual result came in at $7.3 million, down 48.79% from the prior year.
- Share-based Compensation was little changed at $7.3 million in Q4 2025 per MLECW's latest filing, from $7.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $15.9 million in Q2 2024 and troughed at -$323.0 in Q1 2023.
- A 4-year average of $3.6 million and a median of $2.2 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation slumped 100.45% in 2023, then surged 920074.61% in 2024.
- Over 4 years, Share-based Compensation stood at $551841.0 in 2022, then soared by 298.92% to $2.2 million in 2023, then fell by 7.34% to $2.0 million in 2024, then jumped by 258.21% to $7.3 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $7.3 million, $7.3 million, and $2.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.31 Mn |
| Dec 31, 2025 | 7.31 Mn |
| Jun 30, 2025 | 7.27 Mn |
| Jun 30, 2025 | 7.27 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Jun 30, 2024 | 15.91 Mn |
| Jun 30, 2024 | 15.91 Mn |
| Mar 31, 2024 | 2.97 Mn |
| Mar 31, 2024 | 2.97 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Sep 30, 2023 | 1.74 Mn |
| Sep 30, 2023 | 1.74 Mn |
| Jun 30, 2023 | 3.56 Mn |
| Jun 30, 2023 | 3.56 Mn |
| Mar 31, 2023 | -323.00 |
| Mar 31, 2023 | -323.00 |